Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Smilax glabra extract is a botanical preparation derived from the rhizomes of *Smilax glabra* Roxb., a plant widely utilized in Traditional Chinese Medicine (TCM) under the name Tufuling. The extract is primarily investigated for its antimicrobial and anti-inflammatory properties, specifically its ability to inhibit *Helicobacter pylori* infections. Its mechanism of action involves the targeted suppression of urease, a nickel-containing enzyme secreted by *H. pylori* that is essential for the pathogen's survival and colonization in the acidic environment of the stomach. By inhibiting urease, the extract prevents the bacteria from neutralizing gastric acid through ammonia production. The primary bioactive components identified as responsible for this inhibitory effect are the dihydroflavonols astilbin and engeletin.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on smilax glabra extract.